A Phase 3 Study to Evaluate Petosemtamab Plus Pembrolizumab vs Pembrolizumab in First-line Treatment of Head and Neck Cancer (LiGeR - HN1)

This clinical trial is studying whether a new combination of drugs works better than standard treatment for a specific type of head and neck cancer. The study compares the effectiveness of pembrolizumab, a common immunotherapy, given alone versus pembrolizumab given alongside an experimental drug called petosemtamab. Immunotherapy helps your own immune system find and attack cancer cells, while petosemtamab is designed to block specific signals that help tumors grow and spread.

You may be eligible to join if you have been diagnosed with head and neck squamous cell carcinoma that has returned or spread to other parts of the body and cannot be treated with surgery or radiation alone. This trial is specifically for patients who have not yet received systemic treatment, such as chemotherapy or immunotherapy, for their advanced disease. Your tumor must also express a protein called PD-L1, and your cancer must have started in the mouth, throat, or voice box. To participate, you should be in generally good health, have a strong heart, and be able to perform daily activities independently. You will likely need to provide a tissue sample from a biopsy and travel to a clinic for regular intravenous infusions and imaging scans. Before enrolling, you should talk with your doctor about how these treatments are administered, potential side effects, and how this study fits into your long-term care plan.